ARCHIVES

Pertuzumab Delays Progression In HER2-Positive Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 8 | August 26, 2011

Download PDF Visit The Full Archive

Related Articles

Review Of DCCR Programs Uncovers Problems, Assigns Scores To Each

June 30, 1978

Zometa Can Reduce Risk Of Skeletal-Related Events

August 26, 2011

DCT Advisors Approve Five Trials For High Priority Status

April 7, 1995

NCCS Networker Volume 7 Issue 4, Assembly Edition 1993

September 13, 1993

Bezwoda’s ’95 Phase II Study Entirely A Sham, Audit Finds.

April 27, 2001

Conference Level For NCI Is 5.4% Over FY 1990

November 2, 1990